Final data from Antisoma’s AS1404 lung cancer trial show clear survival benefit
Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces final data from its phase II trial of AS1404 in non-small cell lung cancer. These show a very substantial survival benefit.
This entry was posted on Wednesday, September 27th, 2006 at 9:07 am and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.